Novel therapeutic approaches targeting endotypes of severe airway disease

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. .
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al., European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology. 58(Suppl S29): 1–464. 2020. .
   Google Scholar
• Licari A, Castagnoli R, Denicolò CF, et al. The nose and the lung: united airway disease? Front Pediatr. 2017;5:44.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, De Filippo M, et al. Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis. Expert Opin Biol Ther. 2020;20(6):609–619. .
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, Marseglia A, et al. Difficult vs. severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr. 2018;6:170.
   PubMed Web of Science ®Google Scholar
• Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 2015;36(6):418–424.
   PubMed Web of Science ®Google Scholar
• Pijnenburg MW, Fleming L. Advances in understanding and reducing the burden of severe asthma in children. Lancet Respir Med. 2020;8(10):1032–1044.
   PubMed Web of Science ®Google Scholar
• DeConde AS, Soler ZM. Chronic rhinosinusitis: epidemiology and burden of disease. Am J Rhinol Allergy. 2016;30(2):134–139.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Schiavetti I, Rindone E, et al. The impact of anxiety and depression on outpatients with asthma. Ann Allergy Asthma Immunol. 2015;115(5):408–414.
   PubMed Web of Science ®Google Scholar
• Licari A, Ciprandi R, Marseglia G, et al. Anxiety and depression in adolescents with severe asthma and in their parents: preliminary results after 1 year of treatment. Behav Sci (Basel). 2019;9(7):78.
   Google Scholar
• Shin JH, Roh D, Lee DH, et al. Allergic rhinitis and rhinosinusitis synergistically compromise the mental health and health-related quality of life of Korean adults: a nationwide population-based survey. PLoS One. 2018;13(1):e0191115.
   PubMed Web of Science ®Google Scholar
• Epperson MV, McCann AC, Phillips KM, et al. Unbiased Measure of General Quality of Life in Chronic Rhinosinusitis Reveals Disease Modifiers. Laryngoscope. 2021;131(6):1206–1211
   PubMed Web of Science ®Google Scholar
• Erskine SE, Hopkins C, Clark A, et al. Chronic rhinosinusitis and mood disturbance. Rhinology. 2017;55(2):113–119.
   PubMed Web of Science ®Google Scholar
• Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649–1659.
   PubMed Web of Science ®Google Scholar
• Lou H, Wang C, Zhang L. Endotype-driven precision medicine in chronic rhinosinusitis. Expert Rev Clin Immunol. 2019;15(11):1171–1183.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Brambilla I, et al. Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol. 2018;31(2):44–55.
   PubMed Web of Science ®Google Scholar
• Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301.
   PubMed Web of Science ®Google Scholar
• Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12.
   PubMed Web of Science ®Google Scholar
• Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621–628.
   PubMed Web of Science ®Google Scholar
• Agustí A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017;50(4):1701655.
   PubMed Web of Science ®Google Scholar
• Castagnoli R, Marseglia A, Brambilla I, et al. Severe uncontrolled asthma in children: practical approach on diagnosis and management. Minerva Pediatr. 2020;72(3):196–205.
   PubMed Web of Science ®Google Scholar
• Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835–1851.
   PubMed Web of Science ®Google Scholar
• Workman AD, Kohanski MA, Cohen NA. Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. Immunol Allergy Clin North Am. 2018;38(4):679–692.
   PubMed Web of Science ®Google Scholar
• Castagnoli R, Licari A, Manti S, et al. Type-2 inflammatory mediators as targets for precision medicine in children. Pediatr Allergy Immunol. 2020;31(Suppl 26):17–19.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Brambilla I, et al. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin Drug Discov. 2018;13(1):51–63.
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289.
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, et al. Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice. Breathe (Sheff). 2020;16(1):190301.
   PubMedGoogle Scholar
• Bakakos A, Loukides S, Usmani OS, et al. Biologics in severe asthma: the overlap endotype - opportunities and challenges. Expert Opin Biol Ther. 2020;20(12):1427–1434.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725–739.
   PubMed Web of Science ®Google Scholar
• GINA guidelines. Adolescents and adults with difficult to treat and severe asthma. [cited 2021 Jan 28]. Available at:www.ginaasthma.org.
   Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1):1900588.
   PubMed Web of Science ®Google Scholar
• Cloutier MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults: 2020 asthma guideline update from the national asthma education and prevention program. JAMA. 2020;324(22):2301–2317.
   PubMed Web of Science ®Google Scholar
• Akar-Ghibril N, Casale T, Custovic A, et al. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–440.
   PubMed Web of Science ®Google Scholar
• Assaf SM, Hanania NA. Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019;19(4):379–386.
   PubMed Web of Science ®Google Scholar
• Svenningsen S, Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Front Med (Lausanne). 2017;4:158.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Moore WC. Severe asthma phenotypes - how should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5(4):901–908.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Hilvering B, Shrimanker R. Emerging biologics in severe asthma. Immunol Allergy Clin North Am. 2016;36(3):609–623.
   PubMed Web of Science ®Google Scholar
• Narendra D, Blixt J, Hanania NA. Immunological biomarkers in severe asthma. Semin Immunol. 2019 Dec;46:101332.
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323.
   PubMed Web of Science ®Google Scholar
• Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, et al. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267–281.
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224.
   PubMed Web of Science ®Google Scholar
• Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797–1807. .
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Mauger DT, Lemanske RF. Childhood asthma-predictive phenotype. J Allergy Clin Immunol Pract. 2014;2(6):664–670.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Benet M, Saeys Y, et al. Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity cluster. Allergy. 2015;70(8):973–984.
   PubMed Web of Science ®Google Scholar
• Howrylak J, Fuhlbrigge A, Strunk R, et al. Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications. J Allergy Clin Immunol. 2014;133(5):1289–300, 1300.e1-12.
   PubMed Web of Science ®Google Scholar
• Schatz M, Hsu JW, Zeiger RS, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133(6):1549–1556. .
   PubMed Web of Science ®Google Scholar
• Depner M, Fuchs O, Genuneit J, et al. Clinical and epidemiologic phenotypes of childhood asthma. Am J Respir Crit Care Med. 2014;189(2):129–138.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the national institutes of health/national heart, lung, and blood institute severe asthma research program. J Allergy Clin Immunol. 2011;127(2):382–389.e1-13.
   Web of Science ®Google Scholar
• Fitzpatrick AM, Higgins M, Holguin F, et al. National institutes of health/national heart, lung, and blood institute’s severe asthma research program. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol. 2010;125(4):851–857.e18.
   PubMed Web of Science ®Google Scholar
• Just J, Gouvis-Echraghi R, Rouve S, et al. Two novel, severe asthma phenotypes identified during childhood using a clustering approach. Eur Respir J. 2012;40(1):55–60.
   PubMed Web of Science ®Google Scholar
• Fainardi V, Saglani S. The need to differentiate between adults and children when treating severe asthma. Expert Rev Respir Med. 2015;9(4):419–428.
   PubMed Web of Science ®Google Scholar
• Teague WG, Phillips BR, Fahy JV, et al. Baseline Features of the Severe Asthma Research Program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6(2):545–554.e4.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–1008.
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Busby J, Pfeffer PE, et al. UK severe asthma registry. Characterisation of patients with severe asthma in the UK severe asthma registry in the biologic era. Thorax. 2021;76(3):220–227.
   PubMed Web of Science ®Google Scholar
• Kuo CHS, Pavlidis S, Loza M, et al. Th2 and non-Th2 molecular phenotypes of asthma using sputum transcriptomics. Eur Respir J. 2017;49(2):1602135.
   PubMed Web of Science ®Google Scholar
• Papi A, Saetta M, Fabbri L. Severe asthma: phenotyping to endotyping or vice versa? Eur Respir J. 2017;49(2):1700053.
   PubMed Web of Science ®Google Scholar
• Bailey LN, Garcia JAP, Grayson JW. Chronic rhinosinusitis: phenotypes and endotypes. Curr Opin Allergy Clin Immunol. 2021;21(1):24–29.
   PubMed Web of Science ®Google Scholar
• Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol. 2015;11(3):349–361.
   PubMed Web of Science ®Google Scholar
• De Greve G, Hellings PW, Fokkens WJ, et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–1440.
   PubMed Web of Science ®Google Scholar
• Castagnoli R, Licari A, Brambilla I, et al., An update on the role of chronic rhinosinusitis with nasal polyps as a comorbidity in severe asthma. Expert Rev Respir Med. 14(12): 1197–1205. 2020.
   PubMed Web of Science ®Google Scholar
• Bachert C, Marple B, Hosemann W, et al. Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications. J Allergy Clin Immunol Pract. 2020;8(5):1514–1519.
   PubMed Web of Science ®Google Scholar
• Bayar Muluk N, Cingi C, Scadding GK, et al. Chronic rhinosinusitis-could phenotyping or endotyping aid therapy? Am J Rhinol Allergy. 2019;33(1):83–93.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2020 Nov 20;S0091-6749(20):31629.
   Google Scholar
• Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosisof nasal polyps. Am J Rhinol Allergy. 2013;27(6):473–478.
   PubMed Web of Science ®Google Scholar
• Caimmi D, Matti E, Pelizzo G, et al. Nasal polyposis in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):S77–83.
   PubMedGoogle Scholar
• Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med. 2017;11(11):855–865.
   PubMed Web of Science ®Google Scholar
• Lin DC, Chandra RK, Tan BK, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):205–208.
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321.
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319.
   PubMed Web of Science ®Google Scholar
• Stevenson DD, White AA. Clinical characteristics of aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):643–655.
   PubMed Web of Science ®Google Scholar
• Scott WC, Cahill KN, Milne GL, et al. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020;S0091-6749(20):31584.
   Google Scholar
• Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820.e3.
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Hellings P. Biotherapeutics in chronic rhinosinusitis with and without nasal polyps. J Allergy Clin Immunol Pract. 2017;5(6):1512–1516.
   PubMed Web of Science ®Google Scholar
• Turner JH, Chandra RK, Li P, et al. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines. J Allergy Clin Immunol. 2018;141(5):1895–1897.e7.
   PubMed Web of Science ®Google Scholar
• Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol. 2017;139(2):699–703.e7.
   PubMed Web of Science ®Google Scholar
• Li X, Meng J, Qiao X, et al. Expression of TGF, matrix metallopro‐ teinases, and tissue inhibitors in Chinese chronic rhinosinusitis. J Allergy Clin Immunol. 2010;125(5):1061–1068.
   PubMed Web of Science ®Google Scholar
• Cao P‐P, Li H‐B, Wang B‐F, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. 2009;124(3):478–84, 484.e1-2.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353.
   PubMed Web of Science ®Google Scholar
• Lou H, Zhang N, Bachert C, et al. Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement. Int Forum Allergy Rhinol. 2018;8(11):1218‐1225.
   Web of Science ®Google Scholar
• Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012;129(3 Suppl):S9–23.
   PubMed Web of Science ®Google Scholar
• Borrebaeck CA. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer. 2017;17(3):199–204.
   PubMed Web of Science ®Google Scholar
• Carr TF, Kraft M. Use of biomarkers to identify phenotypes and endotypes of severeasthma. Ann Allergy Asthma Immunol. 2018;121(4):414–420.
   PubMed Web of Science ®Google Scholar
• Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121(4):406–413.
   PubMed Web of Science ®Google Scholar
• Uwaezuoke SN, Ayuk AC, Eze JN. Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease. J Asthma Allergy. 2018 15;11:11–18.
   PubMed Web of Science ®Google Scholar
• Zedan MM, Osman AM, Laimon WN, et al. Airway InflammatoryBiomarker: could it tailor the right medications for the right asthmatic patient? Iran J Immunol. 2016;13(2):70–88.
   PubMed Web of Science ®Google Scholar
• Silkoff PE, Laviolette M, Singh D, et al. Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study. Respir Res. 2016 23; 17: 43.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804.
   PubMed Web of Science ®Google Scholar
• Loza MJ, Adcock I, Auffray C, et al. ADEPT and U-BIOPRED investigators.longitudinally stable, clinically defined clusters of patients with asthma independently identified in the ADEPT and U-BIOPRED asthma studies. Ann Am Thorac Soc. 2016;13 (Suppl 1):S102–3.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Siddiqui S, Papi A, et al. Dupilumab efficacy in patients stratified by baseline treatment intensity andlung function. J Asthma Allergy. 2020 Dec;16(13):701–711.
   Web of Science ®Google Scholar
• Licari A, Brambilla I, Sacchi L, et al. Periostin, type 2 biomarker, is not associated with asthma control grade in asthmatic allergic children. Respir Med. 2019 May;151:118–120.
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Scioscia G, Lacedonia D, et al. Looking for airways periostin in severe asthma: couldit be useful for clustering type 2 endotype? Chest. 2018;154(5):1083–1090.
   PubMed Web of Science ®Google Scholar
• McKinley L, Alcorn JF, Peterson A, et al. Th17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181(6):4089–4097.
   PubMed Web of Science ®Google Scholar
• Godar M, Blanchetot C, de Haard H, et al. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. mAbs. 2018;10(1):34–45.
   PubMed Web of Science ®Google Scholar
• Petsky HL, Cates CJ, Kew KM, et al. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110–1119.
   PubMed Web of Science ®Google Scholar
• Froidure A, Mouthuy J, Durham SR. DurhamSR et.al Asthma phenotypes and IgE responses. Eur Respir J. 2016;47(1):304–319.
   PubMed Web of Science ®Google Scholar
• Tiotiu A. Biomarkers in asthma: state of the art. Asthma Res Pract. 2018 21;4:10. .
   PubMedGoogle Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Katz LE, Gleich GJ, Hartley B, et al. eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc. 2014;11(4):531–536.
   PubMedGoogle Scholar
• Bartoli ML, Bacci E, Carnevali S, et al. Quality evaluation of samples obtained by spontaneous or induced sputum: comparison between two methods of processing and relationship with clinical and functional findings. J Asthma. 2002;39(6):479–486.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Jr PR. Treatment of severe, uncontrolled eosinophilic asthma: where we are heading. J Asthma. 2019;56(5):459–472.
   PubMed Web of Science ®Google Scholar
• Kountakis SE, Arango P, Bradley D, et al. Molecular and cellular staging for the severity of chronic rhinosinusitis. Laryngoscope. 2004;114(11):1895–1905.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Yoshikawa M, Asaka D, et al. Mucosal eosinophilia and recurrence of nasal polyps: new classification of chronic rhinosinusitis. Rhinology. 2011;49(4):392–396.
   PubMed Web of Science ®Google Scholar
• Staudacher AG, Peters AT, Kato A, et al. Use of endotypes, phenotypes,and inflammatory markers to guide treatment decisions in chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2020;124(4):318–325.
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124(4):326–332.
   PubMed Web of Science ®Google Scholar
• Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol. 2015;195(8):3537e3545.
   Web of Science ®Google Scholar
• Maxfield AZ, Landegger LD, Brook CD, et al. Periostin as a biomarker for nasal polyps in chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2018;158(1):181–186.
   PubMed Web of Science ®Google Scholar
• Kim DK, Jin HR, Eun KM, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017;72(7):635e645.
   Web of Science ®Google Scholar
• Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1566e1576.
   Web of Science ®Google Scholar
• Licari A, Manti S, Marseglia A, et al. Biologics in children with allergic diseases. Curr Pediatr Rev. 2020;16(2):140–147.
   PubMed Web of Science ®Google Scholar
• Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593e600.
   Web of Science ®Google Scholar
• Barakat L, Torres MJ, Phillips EJ. Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021 Mar 9(3):1396–1399.e2.
   PubMed Web of Science ®Google Scholar
• Giovannini M, Mori F, Barni S, et al. and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose? Ital J Pediatr. 2019;45(1):151.
   PubMed Web of Science ®Google Scholar
• Brodlie M, McKean MC, Moss S. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–609.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015.
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444.
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224–1233.
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–859.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in childhood asthma Italian study group. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13(1):36–42.
   PubMed Web of Science ®Google Scholar
• MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019;15(5):553–569.
   PubMed Web of Science ®Google Scholar
• Heffler E, Paoletti G, Giorgis V, et al. Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Rev Clin Immunol. 2019 Sep;15(9):951–958.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract. 2019 Jan 7(1):156–164.e1.
   PubMed Web of Science ®Google Scholar
• Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy. 2021 Mar 8. doi:https://doi.org/10.1111/all.14809
   Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf 28 Jan 2021
   Google Scholar
• [cited 2021 Jan 28].https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-17
   Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020 Sep;146(3):595.
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kent BD, Jackson DJ. Biologic treatment options for severe asthma. Curr Opin Immunol. 2020 Nov;16(66):151–160.
   Web of Science ®Google Scholar
• Castagnoli R, De Filippo M, Votto M, et al. An update on biological therapies for pediatric allergic diseases. Minerva Pediatr. 2020;72(5):364–371.
   PubMed Web of Science ®Google Scholar
• NUCALA (mepolizumab) EMA approval 2014. [cited 2021 Jan 28] Available from: https://gskprocom/content/
   Google Scholar
• Nucala (mepolizumab) for injection [prescribing information] Research Triangle Park, NC: GlaxoSmithKline. 2015.
   Google Scholar
• Gupta A, Pouliquen I, Austin D, et al., Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 54(12): 1957–1967. 2019.
   PubMed Web of Science ®Google Scholar
• Basu A, Dalal A, Canonica GW, et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):121–131.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double- blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019;41(10):2041–2056.e5.
   PubMed Web of Science ®Google Scholar
• Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336–1342.e7.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726.
   PubMed Web of Science ®Google Scholar
• Wang FP, Liu T, Lan Z, et al. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166833.
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Fouka E, Papakosta D, et al. between biologics in severe asthma patients. When the first choice is not proven to be the best. Clin Exp Allergy. 2021;51(2):221–227.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Hellman C, Lundblad L, et al. Differential expression of the interleukin 5 receptor alpha isoforms in blood and tissue eosinophils of nasal polyp patients. Allergy. 2009;64(5):725–732.
   PubMed Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, et al. SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;S2213-2600(21):00097.
   Google Scholar
• Votto M, De Filippo M, Licari A, et al. Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: a Practical Review. Biologics. 2021;15:133–142.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. BORA study investigators. Benralizumab for adolescent patients with severe, eosinophilic asthma: safety and efficacy after 3 years oftreatment. J Allergy Clin Immunol. 2021 17;S0091-6749(21):00226.
   Google Scholar
• Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo- controlled trial. Clin Exp Allergy. 2021 5836844.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Harrison TW, Chanez P. Benralizumab improves symptoms of patients withsevere, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2021. https://doi.org/10.1111/all.14902.
   Google Scholar
• Tsurumaki H, Matsuyama T, Ezawa K, et al. Rapid effect of benralizumab for hypereosinophilia in a case of severe asthma with eosinophilic chronic rhinosinusitis. Medicina (Kaunas). 2019;55(7):336.
   Web of Science ®Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021;76(1):14–44.
   PubMed Web of Science ®Google Scholar
• Principe S, Porsbjerg C, Bolm Ditlev S. Treating severe asthma: targeting the IL-5 pathway. Clin Exp Allergy. 2021. https://doi.org/10.1111/cea.13885.
   Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133–1141.
   PubMed Web of Science ®Google Scholar
• Boiko NV, Lodochkina OE, Kit MM, et al. Impact of reslizumab on the course of chronic rhinosinusitis in patientswith eosinophilic asthma. Vestn Otorinolaringol. 2021;86(2):43–48. .
   PubMedGoogle Scholar
• Dupilumab FDA Prescribing Information. https://www.acces.sdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. 2020 Jan 19.
   Google Scholar
• Maspero J, Fitzgerald M, Pavord I, et al. Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty asthma quest study. Chest. 2018;154(4Suppl):25A–7A.
   Web of Science ®Google Scholar
• Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133(2):291–307.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Marseglia A, et al., Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Paediatr Drugs. 22(3): 295–310. 2020.
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, Chanez P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41–49.e2.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Pelaia G, Crimi C, et al. Tezepelumab: a potential new biological therapy for severe refractory asthma.Int. J Mol Sci. 2021;22(9):4369.
   Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolledasthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268.
   PubMed Web of Science ®Google Scholar
• Klimek L, Jutel M, Bousquet J, et al. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. Allergy. 2021;76(3):677–688
   PubMed Web of Science ®Google Scholar
• Cardinale F, Ciprandi G, Barberi S, et al., and the SIAIP Task Force. Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Ital J Pediatr. 46(1): 84. 2020.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy. 2020;75(11):2764–2774.
   PubMed Web of Science ®Google Scholar
• Chan S, Chatzipetrou A, Vogelberg C, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: position paper of Ärzteverband Deutscher Allergologen (AeDA) A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI) B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA) C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI) D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI) E, Österreichische Gesellschaft für Pneumologie (ÖGP) F in co-operation with the German, Austrian, and Swiss ARIA groups G, and the European Academy of Allergy and Clinical Immunology (EAACI) H. Allergol Select. 2020 Sep;7(4):53–68.
   Google Scholar
• Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biological therapies: what we need to know. World Allergy Organ J. 2020;13(5):100126.
   PubMed Web of Science ®Google Scholar
• Caminati M, Vultaggio A, Matucci A. Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2020;176:106261.
   PubMed Web of Science ®Google Scholar
• Moeller A, Thanikkel L, Duijts L, et al. COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. ERJ Open Res. 2020;6(4):00409–2020.
   PubMedGoogle Scholar
• Jian L, Yi W, Zhang N, et al. Perspective:COVID-19, implications of nasal diseases and consequences for their management. J Allergy Clin Immunol. 2020;146(1):67–69.
   PubMed Web of Science ®Google Scholar
• Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–2261.
   PubMed Web of Science ®Google Scholar
• Wang H, Song J, Pan L, et al. The characterization of chronic rhinosinusitis in hospitalized patients with COVID-19. J Allergy Clin Immunol Pract. 2020;8(10):3597–3599.e2.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Park JY, Lee HS. Effect of asthma and asthma medication on the prognosis ofpatients with COVID-19. Eur Respir J. 2021;57(3):2002226.
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Almonacid C, González Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3):2003142.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan RK, Al Heialy S, Hamid Q. Implications of preexisting asthma on COVID-19 pathogenesis. Am J Physiol Lung Cell Mol Physiol. 2021;320(5):L880–L891.
   PubMed Web of Science ®Google Scholar
• Naziroğlu T, Aksu K. Rare atopy in COVID-19 patients or COVID-19 famine in atopic patients? Dermatol Ther. 2021;34:e14581
   Google Scholar
• Perlini S, Ciprandi G, Castagnoli R, et al. Eosinopenia could be a relevant prognostic biomarker in patients with coronavirus disease 2019. Allergy Asthma Proc. 2020;41(6):e80–e82.
   PubMed Web of Science ®Google Scholar
• Maes T, Bracke K, Brusselle GG. Reply to Lipworth: inhaledCorticosteroids and COVID-19. Am J Respir Crit Care Med. 2020;202(6):900–902.
   PubMed Web of Science ®Google Scholar
• Hanon S, Brusselle G, Deschampheleire M, et al. COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. Eurn Respir J. 2020;56(6):2002857.
   Web of Science ®Google Scholar
• Bousquet J, Jutel M, Akdis CA, et al. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021;76(3):689–697
   PubMed Web of Science ®Google Scholar
• Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: practical considerations on the organization of an allergy clinic - an EAACI/ARIA position paper. Allergy. 2020 Jun 12: 10.1111/all.14453.
   Google Scholar